OraLiva is building a scalable platform for the early detection of epithelial cancers — starting with oral cancer.

​

Founded by Dr. John McDevitt — a recognized leader in biomedical diagnostics and Professor at NYU — OraLiva was born out of two decades of translational research at the McDevitt Lab, known for its breakthroughs in microfluidics, single-cell analysis, and programmable bioassays. Backed by over two decades and nearly $40M of NIH-funded research, Dr. McDevitt’s vision is now becoming reality: to deliver lab-quality diagnostics into routine care settings through a scalable, AI-powered platform.

​

We are pioneering a new category of point-of-care diagnostics powered by AI-driven cytology. Our core technology, ONC INCYT, is a programmable platform designed to detect morphological changes in individual cells with lab-grade accuracy, speed, and scalability. By combining single-cell analysis with machine learning, ONC INCYT enables real-time cancer screening across a range of high-burden epithelial tissues — including oral, cervical, anal, bladder, and esophageal — using off-the-shelf non-invasive sampling techniques.

​

OraLiva’s first clinical application targets oral cancer — a disease where early detection can mean the difference between life and death and one of the most expensive to treat when diagnosed late. In the U.S., over 59,000 new cases of oral cavity are expected in 2025, with nearly 13,000 deaths. Survival rates drop dramatically from 88% at early stages to just 37% when the disease has metastasized . Economically, the burden is staggering: first-year treatment costs can exceed $108,000 for late-stage cases, compared to less than $8,000 for early-stage treatment .

 

OraLiva’s oral cancer test addresses this urgent gap by empowering dental providers with a fast, non-invasive, and reimbursable screening tool that fits seamlessly into routine care. Our test delivers AI-analyzed cytology results from a simple brush sample, identifying early cellular changes that would otherwise go undetected until advanced disease.

​

OraLiva has secured seed funding for the commercial launch of our product but if you are interesting in learning more about OraLiva please reach out through the form below.